The global HLA typing market is projected to grow from USD 1.7 billion in 2025 to USD 2.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2025 to 2030. Transplantation continues to be the preferred treatment option for many patients suffering from chronic dialysis-dependent end-stage renal disease, as well as those requiring heart, liver, or bone marrow transplants. Over the past decade, significant advancements have been made in HLA typing technologies, antibody monitoring, diagnostic methods, and specialized software developed by various companies. These innovations have become integral to the organ transplantation process, enhancing precision and reliability, and have played a key role in driving the expansion of the HLA typing market.
The commercial service providers segment accounted for the highest growth rate in the HLA typing market, by product and service, during the forecast period.
Based on end-user segmentation, the HLA (Human Leukocyte Antigen) typing market is categorized into commercial service providers, hospitals and transplant centers, and research laboratories and academic institutions. Among these, commercial service providers generated the highest revenue and are expected to witness strong growth, driven by the global rise in organ and stem cell transplants, which require precise, high-throughput HLA typing for effective donor-recipient matching. Growing awareness of personalized medicine, advancements in molecular diagnostics, and the increasing adoption of next-generation sequencing (NGS) technologies are key factors fueling demand for more specialized reagents and kits.The diagnostic applications segment held the largest market share in 2024.
The HLA typing market is categorized based on application into diagnostic applications - including donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, and other diagnostic uses - and research applications. The diagnostic application segment is projected to dominate the market throughout the forecast period, with infectious disease testing accounting for the largest share within this segment. This is largely due to the heightened risk transplant recipients face of acquiring infections from donors. Current donor epidemiological screening methods and laboratory diagnostics have limitations in accurately assessing these risks, making infectious disease testing a critical and continuously growing focus area within the diagnostic segment of the transplant diagnostics market.The market in the North America region is expected to hold a significant market share for the HLA typing market in 2023.
- The HLA typing market spans five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, the market is experiencing strong growth driven by the increasing demand for organ and stem cell transplants, the rising prevalence of chronic and autoimmune diseases, and the adoption of advanced molecular diagnostic techniques. This growth is further supported by a well-established healthcare infrastructure, government initiatives such as the National Marrow Donor Program, and greater public awareness of the importance of accurate HLA matching. The region is a hub for innovation and research, with many leading companies in the HLA typing space headquartered in the region. As a result, cutting-edge technologies, including next-generation sequencing (NGS), are being rapidly adopted, further fueling market expansion.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side: 60% and Demand Side: 40%
- By Designation: Managers: 20%, CXOs & Directors: 30%, and Executives: 50%
- By Region: North America: 40%, Europe: 30%, Asia Pacific: 20%, Latin America: 5%, and Middle East & Africa: 5%
List of Key Companies Profiled in the Report
The prominent players in the HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F. Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), Alpha Biotech Limited (Israel), Bag Diagnostics GmbH (Germany), Caredx, Inc. (US), Creative Biolabs (US), Fujirebio Holdings Inc (Japan), Gendx (Netherlands), Hologic, Inc. (US), Histogenetics LLC (US), Hansa Biopharma AB (Sweden), Illumina, Inc. (US), Inno-Train Diagnostik GmbH (Germany), Immucor, Inc. (US), Krishgen Biosystems (India), Omixon Inc. (Hungary), PacBio (US), Proimmune Ltd (UK), Pacific Bioscience of California Inc. (US), TBG Diagnostics Limited (Australia), and Takara Bio Inc. (Japan), among others.Research Coverage
This report studies the HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).Reasons to buy this report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall HLA typing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.The report provides insights on the following pointers:
- Analysis of key drivers (growing number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding for research activities, growing prevalence of infectious diseases), restraints (high cost of HLA typing products, limited reimbursements for target procedures), opportunities (rising adoption of cross-matching and chimerism testing procedures, growing awareness of organ donations), and challenges (limited number of organ donations and long waiting lists for transplantations, shortage of skilled professionals)
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the HLA typing market
- Market Development: Comprehensive information about lucrative markets
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HLA typing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the HLA typing market.
Table of Contents
1 Introduction
2 Research Methodology
4 Premium Insights
5 Market Overview
6 Hla Typing Market, by Product & Service
7 Hla Typing Market, by Technology
8 Hla Typing Market, by Application
9 Hla Typing Market, by End-user
10 Hla Typing Market, by Region
11 Competitive Landscape
12 Company Profiles
13 Appendix
List of Tables
List of Figures
Companies Mentioned
- BD
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd.
- CareDx, Inc.
- Werfen
- DiaSorin S.p.A.
- TBG Biotechnology Corporation
- Fujirebio
- Eurobio Scientific
- PacBio
- BAG Diagnostics GmbH
- Creative Biolabs
- Histogenetics LLC
- Scisco Genetics, Inc.
- Inno-Train Diagnostik GmbH
- Bionobis
- Takara Bio Inc.
- Krishgen Biosystems
- ScienCell Research Laboratories, Inc.
- ProImmune Ltd.
- Biofortuna Limited
- Alpha Biotech Limited
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 267 |
Published | June 2025 |
Forecast Period | 2025 - 2030 |
Estimated Market Value ( USD | $ 1.7 Billion |
Forecasted Market Value ( USD | $ 2.3 Billion |
Compound Annual Growth Rate | 6.0% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |